Sargent Bickham Lagudis LLC Has $141,000 Holdings in Moderna, Inc. (NASDAQ:MRNA)

Posted by on Apr 2nd, 2023

Sargent Bickham Lagudis LLC boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 14.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 786 shares of the company’s stock after acquiring an additional 100 shares during the period. Sargent Bickham Lagudis LLC’s holdings in Moderna were worth $141,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its holdings in Moderna by 89.9% during the third quarter. Price T Rowe Associates Inc. MD now owns 6,443,409 shares of the company’s stock worth $761,934,000 after acquiring an additional 3,051,035 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Moderna by 108.2% during the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after acquiring an additional 1,984,458 shares in the last quarter. Northern Trust Corp lifted its holdings in Moderna by 0.6% during the first quarter. Northern Trust Corp now owns 3,503,325 shares of the company’s stock worth $603,483,000 after acquiring an additional 20,416 shares in the last quarter. Legal & General Group Plc lifted its holdings in Moderna by 8.3% during the second quarter. Legal & General Group Plc now owns 2,568,811 shares of the company’s stock worth $366,955,000 after acquiring an additional 196,408 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Moderna by 21.1% during the first quarter. Invesco Ltd. now owns 2,128,252 shares of the company’s stock worth $366,611,000 after acquiring an additional 371,311 shares in the last quarter. 63.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on MRNA shares. TD Cowen upgraded Moderna from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $150.00 to $180.00 in a report on Monday, March 13th. Morgan Stanley dropped their target price on Moderna from $205.00 to $185.00 in a report on Thursday, February 23rd. Piper Sandler upped their target price on Moderna from $214.00 to $217.00 and gave the stock an “overweight” rating in a report on Tuesday, December 20th. Royal Bank of Canada began coverage on Moderna in a report on Wednesday, March 1st. They set an “outperform” rating and a $200.00 target price on the stock. Finally, Jefferies Financial Group upgraded Moderna from a “hold” rating to a “buy” rating and upped their target price for the stock from $170.00 to $275.00 in a report on Monday, December 19th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $180.80.

Insider Activity

In other news, Director Noubar Afeyan sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $200.20, for a total value of $2,002,000.00. Following the transaction, the director now owns 2,247,209 shares of the company’s stock, valued at $449,891,241.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction that occurred on Wednesday, January 4th. The stock was sold at an average price of $178.11, for a total transaction of $7,124,400.00. Following the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $963,921,702.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $200.20, for a total value of $2,002,000.00. Following the sale, the director now directly owns 2,247,209 shares in the company, valued at approximately $449,891,241.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 532,337 shares of company stock valued at $88,519,832. 17.30% of the stock is owned by insiders.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $153.58 on Friday. Moderna, Inc. has a twelve month low of $115.03 and a twelve month high of $217.25. The business’s 50 day moving average price is $159.44 and its two-hundred day moving average price is $161.45. The company has a quick ratio of 2.54, a current ratio of 2.73 and a debt-to-equity ratio of 0.05. The company has a market cap of $59.33 billion, a PE ratio of 7.69 and a beta of 1.70.

Moderna (NASDAQ:MRNA – Get Rating) last posted its earnings results on Thursday, February 23rd. The company reported $3.61 EPS for the quarter, missing the consensus estimate of $4.66 by ($1.05). Moderna had a net margin of 43.41% and a return on equity of 46.34%. The firm had revenue of $5.08 billion during the quarter, compared to analyst estimates of $5.02 billion. During the same period in the previous year, the company posted $11.29 EPS. Moderna’s revenue for the quarter was down 29.5% compared to the same quarter last year. On average, analysts predict that Moderna, Inc. will post -2.43 EPS for the current year.

About Moderna

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

See Also

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.